For Q1 FY2026 ended March 31, 2026, Seaport Therapeutics reported a net loss of $25.4 million, a 93.6% increase from the prior year. Operating loss was $27.5 million, up 70.2%. Diluted EPS was -$10.34, compared to -$5.65 a year ago. Cash and cash equivalents totaled $52.9 million, while stockholders' equity was negative $115.6 million.
•Net loss widened to $25.4 million from $13.1 million in Q1 FY2025.
•Operating loss increased to $27.5 million from $16.2 million.
•Diluted EPS of -$10.34 vs. -$5.65 in the prior year quarter.
•Cash balance of $52.9 million; negative equity of $115.6 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and side effects.
All therapeutic candidates in development are based on this platform, with R&D activities focused on neuropsychiatric medicines. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors. Founded in 2024, the company is based in Boston, Massachusetts.
Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines. The company leverages its proprietary Glyph technology platform to create therapeutic candidates for conditions such as depression and anxiety disorders. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and side effects. All of the company's therapeutic candidates are based on this platform, with research and development activities concentrated on neuropsychiatric medicines. Seaport Therapeutics serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors.
Where is Seaport Therapeutics (SPTX) listed and what currency is used?
Seaport Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol SPTX. The stock is traded in US Dollars (USD), reflecting its primary listing in the United States. As a company based in Boston, Massachusetts, and operating in the US healthcare sector, its financial reporting and trading currency are in USD.
What sector and industry does Seaport Therapeutics (SPTX) belong to?
Seaport Therapeutics operates in the Healthcare sector and specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing novel medicines for neuropsychiatric conditions. The biotechnology industry involves using biological processes and technologies to develop therapies, and Seaport's work with its Glyph platform to create treatments for depression and anxiety disorders places it firmly within this industry.
Where is Seaport Therapeutics (SPTX) headquartered?
Seaport Therapeutics is headquartered in Boston, Massachusetts, United States. The company was founded in 2024 and operates primarily from this location. As a clinical-stage biopharmaceutical company, its research and development activities are centered in Boston, which is a major hub for biotechnology and life sciences innovation. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors, primarily within the United States.